Effect of Intratympanic Dexamethasone on Controlling Tinnitus and Hearing loss in Meniere’s Disease

Document Type: Original

Authors

Department of Otorhinolaryngology Head and Neck Surgery. Iran University of Medical Sciences. Hazrate Rasul Medical Center, Tehran, Iran.

Abstract

Introduction:
We investigated the effect of intratympanic dexamethasone on control of tinnitus and hearing loss in patients with Meniere’s disease.
 Materials and Methods:
100 consecutive patients with a diagnosis of Meniere’s disease according to the 1995 criteria of The American Academy of Otolaryngology – Head and Neck Surgery (AAO–HNS) who remained symptomatic despite medical therapy were assigned to receive intratympanic dexamethasone. The results were assessed with respect to changes in hearing symptoms and tinnitus.
 Results:
Hearing improvement and improvement in SDS was observed in 52% and 35% of patients, respectively. Tinnitus score was improved in 57% of patients. There was no relationship between age, sex, duration of disease, unilaterality of disease, or response to therapy.
 Conclusion: 
Intratympanic dexamethasone may be effective in the symptomatic control of hearing loss and tinnitus in Meniere’s disease.

Keywords

Main Subjects


1. Shea JJ Jr, Ge X. Dexamethasone perfusion of the labyrinth plus intravenous dexamethasone for Meniere’s disease. Otolaryngol Clin North Am 1996; 29(2): 353-8.

2. Hillman Todd M, Arriaga Moises A, Chen Douglas A. Intratympanic steroids: do they acutely improve hearing in cases of cochlear hydrops? Laryngoscope 2003; 113(11): 1903-7.

3. Tomoda K, Suzuka Y, Iwai H, YamashitaT, Kumazawa T. Meniere’s disease and autoimmunity: clinical study and survey. Acta otolaryngol suppl 1993; 113: 31-4.                              

4. Houghes GB, Kinner SE, Barna BP, Calabrese LH. Practical versus  theoretical management of autoimmune inner ear disease. Laryngoscope 1984; 94(6):758-67.             

5. Shea JJ. Autoimmune sensorineural hearing loss as an aggravating factor in Meniere’s disease. Adv Otorhinolaryngol 1983; 30: 354-7.

6. ParnesLS, Sun AH, Freeman DJ. Corticosteroid pharmacokinetics in the inner ear fluids: an animal study followed by clinical application. Laryngo- scope 1999; 109: 1-17. 

7. Pondugula SR, Sanneman JD, Wangemann P, Milhaud PG, Marcus DC. Glucocorticoids stimulate cation absorption by semicircular canal duct epithelium via epithelial sodium channel. American Journal Physiol Renal Physiol 2004; 286: F1127-35.

8. Itoh A, Sakata E. Trearment of vestibular disorders. Acta Otolaryngo 1991; 481(suppl):617-23.

9. Shea JJ Jr. the role of dexamethasone or streptomycin perfusion in the treatment of Meniere’s disease. Otolaryngol Clin North Am 1997; 30(6): 1051-59.

10. Silverstein H, Isaacson JE, Olds MJ, Rosenberg S. Dexamethasone inner ear perfusion for the treatment of Meniere’s disease: a prospective, randomized, double-blind, crossover trial. Am J Otol 1998; 19(2): 196- 201.

11.  Hamid MA. Intratympanic dexamethasone perfusion in Meniere’s disease. Presented at the spring meeting of the American Neurotology Society, Palm Desert, CA, May 2001: 12.

12. Selivanova Oksana A, Gouveris H, Victor A, Amedee R, Mann W. Intratympanic dexamethasone and hyaluronic acid in patients with low frequency and Meniere’s- associated sudden sensorineural hearing loss. Otology and neurotology 2005; 26(5): 890-5.       

13. Hamer SG, Driscoll CLW, Facer GW, Beatty  C W, McDonald TJ. Long term follow up of  ranstympanic gentamicin for Meniere’s syndrome.Otology and Neurology 2001; 22(2): 210-4.

14. Soledad Boleas-Aguirre M, Lin FR, Della Santina C, Minor L, Carey J. Longitudinal results with intratympanic dexamethasone in treatment of Meniere’s disease. Otology and Neurotology 2008; 29(1): 33-8.